{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "Cystic fibrosis",
      "SARS-CoV-2",
      "Seroprevalence"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "32828701",
  "DateCompleted": {
    "Year": "2020",
    "Month": "12",
    "Day": "30"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "02",
    "Day": "01"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2020",
        "Month": "08",
        "Day": "11"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.jcf.2020.08.005",
      "S1569-1993(20)30821-3"
    ],
    "Journal": {
      "ISSN": "1873-5010",
      "JournalIssue": {
        "Volume": "19",
        "Issue": "6",
        "PubDate": {
          "Year": "2020",
          "Month": "Nov"
        }
      },
      "Title": "Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society",
      "ISOAbbreviation": "J Cyst Fibros"
    },
    "ArticleTitle": "SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.",
    "Pagination": {
      "StartPage": "872",
      "EndPage": "874",
      "MedlinePgn": "872-874"
    },
    "Abstract": {
      "AbstractText": [
        "In Belgium, COVID-19 epidemy began on February 4, 2020 with a peak on April 10, 2020. Patients with cystic fibrosis (CF) followed in the Cliniques universitaires Saint-Luc were rapidly isolated before the government lockdown.",
        "After the peak of the epidemy, we measured anti-SARS-CoV-2 IgM and IgG antibodies in 149 patients and collected clinical data.",
        "Only 3 asymptomatic patients presented IgG against the virus. In one patient hospitalized for COVID-19 (positive molecular testing), we did not detect any anti-SARS-CoV-2 antibodies, as in thirty-five other symptomatic patients considered as possible cases.",
        "Even if respiratory symptoms linked to CF are frequent and compatible with COVID-19, anti-SARS-CoV-2 IgG antibodies were detected only in 3 asymptomatic patients. This reassuring study concerning the risk of COVID-19 in patients with CF illustrates the difficulty to distinguish COVID-19 symptoms from respiratory exacerbations and the need of generalized molecular testing to make a precise diagnosis."
      ],
      "CopyrightInformation": "Copyright \u00a9 2020. Published by Elsevier B.V."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Centre de r\u00e9f\u00e9rence pour la mucoviscidose, Cliniques universitaires Saint-Luc, Brussels, Belgium; Department of Pediatrics, Cliniques universitaires Saint-Luc, Brussels, Belgium."
          }
        ],
        "LastName": "Berardis",
        "ForeName": "S",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of medical biology and microbiology, Cliniques universitaires Saint-Luc, Brussels, Belgium."
          }
        ],
        "LastName": "Verroken",
        "ForeName": "A",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Centre de r\u00e9f\u00e9rence pour la mucoviscidose, Cliniques universitaires Saint-Luc, Brussels, Belgium."
          }
        ],
        "LastName": "Vetillart",
        "ForeName": "A",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Centre de r\u00e9f\u00e9rence pour la mucoviscidose, Cliniques universitaires Saint-Luc, Brussels, Belgium."
          }
        ],
        "LastName": "Struyf",
        "ForeName": "C",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Centre de r\u00e9f\u00e9rence pour la mucoviscidose, Cliniques universitaires Saint-Luc, Brussels, Belgium."
          }
        ],
        "LastName": "Gilbert",
        "ForeName": "M",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of medical biology and microbiology, Cliniques universitaires Saint-Luc, Brussels, Belgium."
          }
        ],
        "LastName": "Gruson",
        "ForeName": "D",
        "Initials": "D"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Centre de r\u00e9f\u00e9rence pour la mucoviscidose, Cliniques universitaires Saint-Luc, Brussels, Belgium; Department of Pneumology, Cliniques universitaires Saint-Luc, Brussels, Belgium; Pole of Pneumology, ENT and Dermatology, Institute of Experimental & Clinical Research, Universit\u00e9 catholique de Louvain (UCLouvain), Brussels, Belgium. Electronic address: sophie.gohy@uclouvain.be."
          }
        ],
        "LastName": "Gohy",
        "ForeName": "S",
        "Initials": "S"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Netherlands",
    "MedlineTA": "J Cyst Fibros",
    "NlmUniqueID": "101128966",
    "ISSNLinking": "1569-1993"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antibodies, Viral"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [
        "analysis"
      ],
      "DescriptorName": "Antibodies, Viral"
    },
    {
      "QualifierName": [
        "epidemiology"
      ],
      "DescriptorName": "Asymptomatic Infections"
    },
    {
      "QualifierName": [
        "epidemiology"
      ],
      "DescriptorName": "Belgium"
    },
    {
      "QualifierName": [
        "epidemiology",
        "immunology",
        "prevention & control",
        "therapy"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "methods",
        "statistics & numerical data"
      ],
      "DescriptorName": "COVID-19 Serological Testing"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Communicable Disease Control"
    },
    {
      "QualifierName": [
        "diagnosis",
        "epidemiology"
      ],
      "DescriptorName": "Cystic Fibrosis"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Diagnosis, Differential"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [
        "statistics & numerical data"
      ],
      "DescriptorName": "Hospitalization"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Outcome Assessment, Health Care"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Risk Assessment"
    },
    {
      "QualifierName": [
        "immunology",
        "isolation & purification"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Seroepidemiologic Studies"
    }
  ],
  "CoiStatement": "Declaration of Competing Interest The authors have declared that no conflict of interest exists."
}